IOmx Therapeutics AG

BRIEF

published on 12/19/2024 at 14:05, 2 days 5 hours ago

IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application

Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
PRESS RELEASE

published on 12/19/2024 at 14:00, 2 days 5 hours ago

iOmx Therapeutics submits Clinical Trial Application for IOMX-0675
iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function

Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF

published on 08/22/2024 at 10:05, 3 months 30 days ago

IOmx Therapeutics Initiates Phase Ib with OMX-0407

Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
PRESS RELEASE

published on 08/22/2024 at 10:00, 3 months 30 days ago

iOmx Therapeutics Initiates Phase Ib with OMX-0407
iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma

Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF

published on 06/27/2024 at 10:05, 5 months 24 days ago

IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer

Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
PRESS RELEASE

published on 06/27/2024 at 10:00, 5 months 24 days ago

iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer
iOmx Therapeutics appoints Florian Schmid as new Chief Financial Officer, succeeding Marcus Irsfeld. Schmid brings 20+ years of financial leadership experience in biopharma. Company aims to advance immuno-oncology drug candidates

Chief Financial Officer Biopharmaceutical Immuno-oncology IOmx Therapeutics Florian Schmid
PRESS RELEASE

published on 11/01/2023 at 10:00, 1 year 1 month ago

iOmx Therapeutics attends upcoming scientific and industry conferences
PRESS RELEASE

published on 09/05/2023 at 08:30, 1 year 3 months ago

iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer
PRESS RELEASE

published on 04/04/2023 at 10:00, 1 year 8 months ago

iOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical Trial
PRESS RELEASE

published on 02/23/2023 at 10:00, 1 year 9 months ago

iOmx Therapeutics appoints Dr. Christine Rothe as new Chief Development Officer

Published on 12/21/2024 at 01:30, 17 hours 35 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 35 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 19 hours 5 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 35 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 18 hours 13 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 20 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 54 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 6 hours 47 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News